Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel Free SABSW Stock Alerts

SAB Biotherapeutics (SABSW) Competitors

SAB Biotherapeutics logo
$0.01 0.00 (-0.72%)
As of 06/26/2026 03:42 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

SABSW vs. AIMDW, ALVOW, ARAV, ACABW, and BFRIW

Should you buy SAB Biotherapeutics stock or one of its competitors? MarketBeat compares SAB Biotherapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with SAB Biotherapeutics include Ainos (AIMDW), Alvotech (ALVOW), Aravive (ARAV), Atlantic Coastal Acquisition Corp. II (ACABW), and Biofrontera (BFRIW). These companies are all part of the "pharmaceutical products" industry.

How does SAB Biotherapeutics compare to Ainos?

SAB Biotherapeutics (NASDAQ:SABSW) and Ainos (NASDAQ:AIMDW) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

In the previous week, SAB Biotherapeutics and SAB Biotherapeutics both had 2 articles in the media. Ainos' average media sentiment score of 1.43 beat SAB Biotherapeutics' score of 0.44 indicating that Ainos is being referred to more favorably in the news media.

Company Overall Sentiment
SAB Biotherapeutics Neutral
Ainos Positive

Company Net Margins Return on Equity Return on Assets
SAB BiotherapeuticsN/A N/A N/A
Ainos N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SAB BiotherapeuticsN/AN/AN/AN/AN/A
Ainos$18.11KN/AN/AN/AN/A

Summary

Ainos beats SAB Biotherapeutics on 2 of the 2 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Alvotech?

Alvotech (NASDAQ:ALVOW) and SAB Biotherapeutics (NASDAQ:SABSW) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alvotech$559.42MN/AN/AN/AN/A
SAB BiotherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
AlvotechN/A N/A N/A
SAB Biotherapeutics N/A N/A N/A

In the previous week, Alvotech and Alvotech both had 2 articles in the media. Alvotech's average media sentiment score of 0.93 beat SAB Biotherapeutics' score of 0.44 indicating that Alvotech is being referred to more favorably in the media.

Company Overall Sentiment
Alvotech Positive
SAB Biotherapeutics Neutral

Summary

Alvotech beats SAB Biotherapeutics on 2 of the 2 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Aravive?

SAB Biotherapeutics (NASDAQ:SABSW) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

35.8% of Aravive shares are owned by institutional investors. 60.4% of Aravive shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SAB BiotherapeuticsN/AN/AN/AN/AN/A
AraviveN/AN/AN/A-$0.90N/A

In the previous week, SAB Biotherapeutics had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for SAB Biotherapeutics and 0 mentions for Aravive. SAB Biotherapeutics' average media sentiment score of 0.44 beat Aravive's score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
SAB Biotherapeutics Neutral
Aravive Neutral

Company Net Margins Return on Equity Return on Assets
SAB BiotherapeuticsN/A N/A N/A
Aravive N/A N/A N/A

Summary

SAB Biotherapeutics and Aravive tied by winning 2 of the 4 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Atlantic Coastal Acquisition Corp. II?

SAB Biotherapeutics (NASDAQ:SABSW) and Atlantic Coastal Acquisition Corp. II (NASDAQ:ACABW) are both pharmaceutical products companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

In the previous week, SAB Biotherapeutics had 2 more articles in the media than Atlantic Coastal Acquisition Corp. II. MarketBeat recorded 2 mentions for SAB Biotherapeutics and 0 mentions for Atlantic Coastal Acquisition Corp. II. SAB Biotherapeutics' average media sentiment score of 0.44 beat Atlantic Coastal Acquisition Corp. II's score of 0.00 indicating that SAB Biotherapeutics is being referred to more favorably in the media.

Company Overall Sentiment
SAB Biotherapeutics Neutral
Atlantic Coastal Acquisition Corp. II Neutral

Company Net Margins Return on Equity Return on Assets
SAB BiotherapeuticsN/A N/A N/A
Atlantic Coastal Acquisition Corp. II N/A N/A N/A

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
SAB BiotherapeuticsN/AN/AN/AN/AN/A
Atlantic Coastal Acquisition Corp. IIN/AN/AN/AN/AN/A

Summary

SAB Biotherapeutics beats Atlantic Coastal Acquisition Corp. II on 2 of the 2 factors compared between the two stocks.

How does SAB Biotherapeutics compare to Biofrontera?

Biofrontera (NASDAQ:BFRIW) and SAB Biotherapeutics (NASDAQ:SABSW) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, valuation, earnings, risk, analyst recommendations and media sentiment.

In the previous week, Biofrontera and Biofrontera both had 2 articles in the media. Biofrontera's average media sentiment score of 1.44 beat SAB Biotherapeutics' score of 0.44 indicating that Biofrontera is being referred to more favorably in the media.

Company Overall Sentiment
Biofrontera Positive
SAB Biotherapeutics Neutral

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biofrontera$43.20MN/AN/AN/AN/A
SAB BiotherapeuticsN/AN/AN/AN/AN/A

Company Net Margins Return on Equity Return on Assets
BiofronteraN/A N/A N/A
SAB Biotherapeutics N/A N/A N/A

Summary

Biofrontera beats SAB Biotherapeutics on 2 of the 2 factors compared between the two stocks.

Get SAB Biotherapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for SABSW and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SABSW vs. The Competition

Export
MetricSAB BiotherapeuticsBiotechnology IndustryMedical SectorNASDAQ Exchange
Market CapN/A$499.79M$6.84B$12.20B
Dividend YieldN/A3.87%2.66%6.22%
P/E RatioN/A3.1726.0224.37
Price / SalesN/A6,785.72549.39102.32
Price / CashN/A13.1329.0936.93
Price / BookN/A89.3710.986.49
Net IncomeN/A-$96.07M$3.57B$336.61M
7 Day PerformanceN/A0.54%2.60%1.25%
1 Month PerformanceN/A-0.45%0.93%0.24%
1 Year PerformanceN/A72.39%36.40%30.16%

SAB Biotherapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
SABSW
SAB Biotherapeutics
N/A$0.01
-0.7%		N/A-51.8%$0.00N/AN/A140
AIMDW
Ainos
N/A$0.14
-0.4%		N/A-16.0%$0.00$18.11KN/A40
ALVOW
Alvotech
N/A$0.25
flat		N/AN/A$0.00$559.42MN/A4
ARAV
Aravive
N/A$0.04
flat		N/AN/A$0.00N/AN/A20
ACABW
Atlantic Coastal Acquisition Corp. II
N/A$0.00
flat		N/AN/A$0.00N/AN/A15

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:SABSW) was last updated on 6/30/2026 by MarketBeat.com Staff.
From Our Partners
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
The startup growing 23 times faster than Nvidia
An official SEC document contains a name Elon Musk revealed on page 146 - a startup that one analyst believes ...
Brownstone Research | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...
Banyan Hill Publishing | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel